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Introduction
The eternal problem faced in service provision is that of
coping with an ever-increasing work-load within the relative
constraints of keeping costs down to a minimum. The reasons
for the increase in the work-load are multiple and include the
need to expand the repertoire of tests available if so justified.
The justification in medical practice is not only limited to
evidence-based proof of the use of medicinals, but is also
extendable to the usage of laboratory tests. Regrettably,
laboratory usage still appears to be rooted in the mentality that
if the test is available, then its request may just be justified in
the case that it throws up an abnormal result. This article aims
to look at some commonly requested and possibly over-
requested tests as well as discusses the value of emerging tests
that may well help the rationalisation of other over-stretched
medical services.
To oGTT or not oGTT
The oral glucose tolerance test has seen its usage change
with the review in the diagnostic criteria for diabetes mellitus.
It is a cumbersome and lengthy test, that is subject, for its
accuracy in diagnosis, in the patient remaining on a
carbohydrate-rich diet in the days prior to its undertaking.
The oGTT seeks to make a diagnosis using two different
criteria; (a) the fasting blood glucose which in some individuals
eg obese subjects may be sufficient to diagnose diabetes and
(b) the 2 hour value which is more likely to be diagnostic in
other individuals (eg the elderly).1  Current guidelines
recommend screening adults over the age of 45 years for
diabetes with a fasting blood glucose (FBG) and the oGTT is
only indicated in those with FBG between 6.1 and 7.0 mmol/l.
The FBG cut-off of 7.0mmol/l was chosen because it
corresponds roughly with a 2 hour value of 11.1mmol/l. However
nearly one third of Europeans with diagnostic 2 hour values
have “normal” (≤6mmol/l) FBGs simply because they are a less
obese population than the ones from which the new diagnostic
criteria were established.2  To extend the oGTT in an open-ended
fashion to this population group is frankly impossible in the
current setting.
The role of the HbA1c as a diagnostic tool has been
repeatedly looked at. A meta-analysis of 34 studies confirmed
that that while an HbA1c result above the upper reference limit
is relatively specific for glucose intolerance,3 a “normal” value
does not exclude it.4  The HbA1c cannot be used as a screening
test in its own right but may be combined with FBG to try and
avoid unnecessary oGTTs5. In patients pre-selected on the
strength of risk factors of obesity, dyslipidaemia, hypertension,
previous history of impaired glucose tolerance and a positive
family history of diabetes, the authors found that subjects with
a FBG ≤6mmol/l and a HbA1c of 5.6% had a sensitivity of 72%
and a specificity of 77% to predict a 2 hour plasma glucose level
≥7.8mmol/l.5
Liver enzymes – what’s normal?
The liver function profile is frequently used to screen for
liver disease in patients with non-specific symptoms and is also
used as a baseline investigation prior to the commencement of
potentially hepatotoxic drug therapy eg statins. The finding of
persistent, unexplained mild to moderate increases in liver
transaminases is a frequent occurrence raising questions as to
what the normal upper reference limits should be.6 A recent
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large-scale survey in the USA showed that the prevalence of
elevated ALT is 7.9% of which 69% is unexplained.7 In both
sexes, otherwise unexplained elevated ALT is significantly
associated with with higher body mass index, waist
circumference, serum triglycerides, fasting insulin  and lower
HDL-cholesterol, all features of the metabolic syndrome.
Patients with non-alcoholic fatty liver disease (NAFLD) show
hepatic and peripheral insulin resistance of a degree similar to
that observed in diabetes mellitus type 2.8 Apart from being a
marker for NAFLD, serum ALT, but not AST, can also predict
the future development of type 2 DM independently of other
known risk factors.9  Men with ALT levels >29U/l at baseline
have a 3-fold risk of developing DM compared to those with
levels <17U/l. Serum gamma-GT correlates with ALT and is
similarly associated with metabolic syndrome and predicts the
development of type 2 diabetes mellitus.10
PSA – a victim of its own success?
Prostate-specific antigen is the most widely requested
among the various tumour markers available. In this age of
evidence-based medicine, it becomes extremely relevant to re-
evaluate our position as to whether we are using or abusing this
diagnostic tool. The number of requests that come through to
the biochemistry laboratory has shown phenomenal growth,
indicating the increased awareness of prostate cancer as one of
the primary cancers affecting men and the general desire to pick
this up at as early a stage as possible.
PSA has been around for more than 20 years and when
originally described in the New England Journal of Medicine, a
40 to 50% relationship was found to exist between the blood
PSA and the size of the cancer. A study spanning 20 years, using
data from 1300 prostate tissue samples collected at Stanford
University, divided the numbers sampled into four consecutive
five-year periods and compared the volume and the grade of
cancer with the clinical findings found on digital rectal
examination  and the blood PSA levels. Over time, the
correlation weakened from a predictive ability of 43% in the
first 5 years to 2% in the last 5 years.11
Given these values, PSA can no longer be considered to have
any significant relationship to prostate cancer except for 2% of
men. PSA is now related only to benign prostatic hypertrophy
for levels of blood PSA between 2 and 10 µg/l and possibly in a
lot of cases of PSA levels up to 20µg/l. It is difficult to explain
exactly why this phenomenon has happened but it is probably
due to over-screening and the removal of all of the big cancers.
Also, it is important to realise the incidence of prostate cancer
and its ubiquitous nature. 8% of men in their twenties already
have cancer cells in their prostate and the numbers grow with
each decade until 70% of men in their seventies have prostate
cancer. Despite these terrifying figures, the death rate from
prostate cancer is 226 per 100,000 men over the age of 65 years.
The low specificity of PSA for prostatic cancer results in a
high proportion of unnecessary biopsies. In the absence of
alternative and better tumour markers for screening purposes,
the use of complexed and free isoforms of PSA may serve as a
potential method of increasing the ability to discriminate
between those patients with benign disease and those with
prostate cancer. In unscreened populations, there are significant
differences in the total and complexed PSA concentrations, in
the total-to-total PSA ratio and in the free-to-total PSA ratio in
patients with prostate cancer compared with those with benign
disease. The corresponding specificities are similar. In such a
population, the use of PSA isoform concentrations and their
ratios does not provide additional discriminatory power. In the
subset of patients with total PSA levels between 2 and 10 µg/l,
the free-to-total PSA ratio at a cut-off point of 16.5% is superior
to total PSA concentration (42 vs. 20%) in discriminating
between benign and malignant disease.  PSA remains a very
good tool for the monitoring of treatment for patients already
diagnosed with  and treated for prostate cancer by either surgery
or irradiation. It is so not on account of its cancer specificity
but on account of its prostate specificity.
Remaining on the theme of prostatic carcinoma, the primary
prevention of this condition is an attractive and appropriate
target because of its incidence, prevalence and disease-related
mortality as well as its long latency and molecular pathogenesis.
Epidemiological data indicates that a number of environmental
factors modify the risk. Selenium and Vitamin E have been
shown in SELECT (Selenium and Vitamin E Cancer Prevention
Trial) to prevent prostate cancer.12  Vitamin D may also be
preventative and reduced blood levels of active vitamin D result
in a higher incidence and a higher mortality rate from prostate
cancer. Preclinical work has also demonstrated that vitamin D
exerts an antiproloferative effect on prostate cancer cells.13  Daily
use of soy products has also been associated with a 70%
reduction in the risk of developing prostate cancer. Lycopene,
derived in food-form but not as a pure pharmaceutical agent, is
also associated with a lower risk of prostate cancer. Green tea,
on account of its polyphenol content, also explains the low
incidence of prostate cancer in those Asian men who show a
high dietary intake.14 Unfortunately not all of what is usually
considered good is indeed good for prostate cancer. Men with
the highest quartile levels for folate and vitamin B12 show odds
ratios for prostate cancer risk of 1.6 and 2.3 respectively,
compared to subjects in the lowest quartiles. 15
Cardiovascular disease – drowning under its
own labour-intensive work-load!
Biochemical markers
for better coronary risk stratification
Despite the intense interest and massive funding into
cardiovascular disease, a number of unanswered questions and
worrying statistics remain with us even now. Approximately
30% of coronary heart disease (CHD)-related deaths occurs in
individuals with no prior indications of the disease, partially
because more than 65% of acute myocardial infarctions occur
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in vessels with less than 50% stenosis. This accentuates the
importance of the identification of biochemical markers for the
early diagnosis and treatment of CHD. The standard risk factors
e.g. total cholesterol, LDL-cholesterol, HDL-cholesterol, age,
gender, etc explain only a small percentage of CHD deaths. Total
and LDL-cholesterol are not prerequisites for coronary heart
disease. The discovery of new risk factors and causal pathways
continue to aid our understanding of atherogenesis. Some novel
risk factors for atherosclerosis include homocysteine,
fibrinogen, impaired fibrinolysis, platelet reactivity,
hypercoagulability, infections, inflammation, antioxidants and
oxidation of LDL and body iron.
Considering just LDL factors, univariate analysis indicates
that LDL particle size and number are significantly associated
with cardiovascular event risk in both men and women.
However on multivariate analysis, particle size becomes non-
significant and only LDL particle number remains a significant
predictor. LDL particle testing should be restricted to high-risk
patients in order to optimize their cholesterol profile.16
The association of oxidized LDL with atherosclerosis is
significant. Patients with symptomatic ischaemic heart disease
differ significantly from healthy persons with
hypercholesterolaemia by having lower levels of LDL-oxidative
potential and LDL-a tocopherol concentrations. No such
differences exist in plasma anti-oxidant concentrations as
measured by plasma a-tocopherol, plasma retinol and ascorbic
acid or in parameters of body iron content e.g. ferritin,
transferin, serum iron.17
It is important to realize that atherosclerosis is an
inflammatory condition and managing  inflammation may be
just as important as lowering levels of LDL-cholesterol. Various
inflammatory markers are now available and include hs-CRP.
CRP is directly involved in atheromatous plaque
vulnerability and systemic inflammation is associated with
multifocal plaque disruption and the development of acute
coronary events. CRP plays a part in plaque build-up and use of
the statin drugs in lowering cholesterol also lowers CRP levels,
thereby slowing and even reversing atherosclerosis. Patients
may achieve target cholesterol levels but if their CRP levels
remain elevated, then the amount of benefit derived from statin
therapy is limited. In heart disease patients, the goal should be
to lower CRP levels to below 2mg/l.18 Elevated CRP levels are
known to be associated with raised concentrations of
biochemical markers of endothelial and macrophage activation
e.g. cellular adhesion molecules (CAMs) and matrix
metalloproteinases (MMPs). These molecules play a pathogenic
role in atheromatous plaque vulnerability and rapid coronary
stenosis progression.19
Biochemistry markers in the diagnosis
of ischaemic heart disease
The role of the biochemistry laboratory in cardiovascular
disease now extends beyond coronary risk stratification and the
retrospective detection of cardiac tissue necrosis by CK-MB and
cardiac troponins. It can become an invaluable aid in the
diagnosis of ischaemic heart disease and in the differentiation
of chest pain of suspected ischaemic origin. Ischaemia-modified
albumin (IMA) is one such marker that has the ability to modify
the management of chest pain.
Differentiating transient myocardial ischaemia or angina
from non-cardiac causes of chest pain is a major diagnostic
challenge. Acute ST elevation myocardial infarction (MI) is in
most instances picked up through examination of a standard 12
lead electrocardiogram. It is also possible to identify a non-STE
MI, and acute coronary syndromes through detection of raised
myocardial enzymes. But once either of these two conditions
are excluded, chest pain patients cannot be informed whether
they are at risk for any acute myocardial event. The inability to
identify occult cardiac disease is compounded by the potential
for sudden cardiac death in patients with unrecognised
significant coronary artery lesions.
The classic approaches of clinical assessment, provocative
testing, or advanced imaging studies do not truly meet the
practice needs of emergency practitioners due to problems of
false negative and positive outcomes 20, limited logistics in
arranging such tests or limited access to the medical specialists
needed to interpret them.
The IMA assay presents a quantitative accurate laboratory
determination of the occurrence of an ischaemic myocardial
event; angina pectoris. Unlike previous serum studies that
identify myocardial damage after the fact, this test allows
emergency physicians to determine which patients have
potential coronary artery lesions before occlusion occurs. The
IMA assay when combined with the ECG and troponin T
demonstrates a 95% sensitivity, a value which matches that of
any other diagnostic modality short of coronary artery
catheterisation. Considering the potential consequences for
missing the presence of clinically significant coronary lesions
the introduction of an objective decisions tool for these patients
is a welcome aid to even the most confident clinician.21
Biochemical markers in the diagnosis and
management of congestive heart failure
In congestive heart failure, plasma levels of brain natriuretic
peptide (BNP) are useful in differentiating dyspnoea secondary
to cardiac dysfunction (BNP levels generally 1000 to 4000 mg/
l) from dyspnoea due to pulmonary conditions (BNP levels <
100 mg/ l).22  Patients with congestive heart failure are clinically
misdiagnosed 50-75% of the time. BNP is synthesized in the
ventricles of the heart and secreted under conditions of
myocardial stretch and abnormal wall tension. Use of BNP can
help in the triage of patients and can serve as a valuable tool in
the early diagnosis and treatment of patients with heart failure.
It also optimizes the choice of patients who require
echocardiography. Plasma BNP levels fall rapidly with successful
anti-heart failure treatments,23 this being most likely due the
reversal of the pathological remodeling process that occurs
following neurohormonal blockade.
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